Publications
Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration
Detaille D et al. — 2016, published online 18 January 2016
Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model
Vial G et al. — 2015 Jun;64(6):2254-64.
Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes
Pacini G et al. — 2015 Jun;17(6):541-5.
The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy
Fouqueray P et al. — 2014 Jul;37(7):1924-30.
The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy
Fouqueray P et al. — 2013 Mar;36(3):565-8.
Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients
Pirags V et al. — 2012 Sep;14(9):852-8.
Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes
Fouqueray P et al. — 2011 May 2:126.